BRPI0713371A2 - método para a produção de um produto medicamentoso contendo olmesartan medoxomil, e, produto medicamentoso contendo olmesartan medoxomil - Google Patents

método para a produção de um produto medicamentoso contendo olmesartan medoxomil, e, produto medicamentoso contendo olmesartan medoxomil Download PDF

Info

Publication number
BRPI0713371A2
BRPI0713371A2 BRPI0713371-5A BRPI0713371A BRPI0713371A2 BR PI0713371 A2 BRPI0713371 A2 BR PI0713371A2 BR PI0713371 A BRPI0713371 A BR PI0713371A BR PI0713371 A2 BRPI0713371 A2 BR PI0713371A2
Authority
BR
Brazil
Prior art keywords
olmesartan medoxomil
containing olmesartan
medicament containing
producing
medoxomil
Prior art date
Application number
BRPI0713371-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Yada Shuichi
Hasegawa Susumu
Tanimoto Mitsuhide
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38845498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0713371(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of BRPI0713371A2 publication Critical patent/BRPI0713371A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0713371-5A 2006-06-27 2007-06-26 método para a produção de um produto medicamentoso contendo olmesartan medoxomil, e, produto medicamentoso contendo olmesartan medoxomil BRPI0713371A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006-176146 2006-06-27
JP2006176146 2006-06-27
PCT/JP2007/062734 WO2008001734A1 (en) 2006-06-27 2007-06-26 Compressed preparation

Publications (1)

Publication Number Publication Date
BRPI0713371A2 true BRPI0713371A2 (pt) 2012-03-13

Family

ID=38845498

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713371-5A BRPI0713371A2 (pt) 2006-06-27 2007-06-26 método para a produção de um produto medicamentoso contendo olmesartan medoxomil, e, produto medicamentoso contendo olmesartan medoxomil

Country Status (9)

Country Link
US (1) US20100237530A1 (cg-RX-API-DMAC7.html)
EP (1) EP2033643A4 (cg-RX-API-DMAC7.html)
JP (2) JP5769362B2 (cg-RX-API-DMAC7.html)
KR (1) KR101628028B1 (cg-RX-API-DMAC7.html)
CN (1) CN101478966B (cg-RX-API-DMAC7.html)
BR (1) BRPI0713371A2 (cg-RX-API-DMAC7.html)
CA (1) CA2656181C (cg-RX-API-DMAC7.html)
TW (1) TWI492747B (cg-RX-API-DMAC7.html)
WO (1) WO2008001734A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2253318B1 (en) 2008-03-13 2014-08-06 Daiichi Sankyo Company, Limited Improvement of dissolvability of preparation containing olmesartan medoxomil
JP2011136908A (ja) * 2009-12-25 2011-07-14 Kyowa Yakuhin Kogyo Kk アンギオテンシンｉｉ受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンｉｉ受容体拮抗剤の保存安定性向上方法
CN102119930B (zh) * 2010-07-13 2013-01-30 福建天泉药业股份有限公司 一种奥美沙坦酯片及制备方法
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
CN102028663B (zh) * 2010-12-14 2011-11-30 北京万生药业有限责任公司 一种稳定的奥美沙坦酯固体制剂
WO2013147462A1 (en) * 2012-03-30 2013-10-03 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
CN105663070A (zh) * 2014-11-21 2016-06-15 深圳信立泰药业股份有限公司 一种含有奥美沙坦酯的药物组合物及其制备方法
CN105640913B (zh) * 2016-01-22 2018-11-02 山东省医学科学院药物研究所 一种奥美沙坦酯片及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
JPH0282519A (ja) 1988-09-19 1990-03-23 Sanyo Electric Co Ltd 固相エピタキシャル成長方法
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
AU743109B2 (en) * 1998-07-15 2002-01-17 Asahi Kasei Kabushiki Kaisha Excipient
JP3796562B2 (ja) * 1999-05-26 2006-07-12 ライオン株式会社 多層錠、多層錠の製造方法及び多層錠の剥離抑制方法
CA2414945C (en) * 2000-07-05 2006-07-04 Asahi Kasei Kabushiki Kaisha Cellulose powder
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
US20040132731A1 (en) * 2002-06-26 2004-07-08 Fox David Nathan Abraham Novel combination
KR20120058618A (ko) * 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
WO2005014043A1 (en) 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
EP1674083B1 (en) * 2003-10-15 2018-08-01 Fuji Chemical Industry Co., Ltd. Tablet quickly disintegrating in oral cavity
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
KR100952090B1 (ko) 2003-10-31 2010-04-13 다케다 야쿠힌 고교 가부시키가이샤 인슐린 감작제, 인슐린 분비촉진제 및 폴리옥시에틸렌소르비탄 지방산 에스테르를 함유하는 고체 제제
JP4437141B2 (ja) 2004-09-02 2010-03-24 テバ ファーマシューティカル インダストリーズ リミティド オルメサルタンメドキソミルの精製法
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
TWI407978B (zh) * 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法
CN101247832B (zh) * 2005-06-27 2011-12-28 第一三共株式会社 含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂
SI1891952T1 (sl) 2006-05-04 2012-02-29 Lek Pharmaceuticals, D.D. Farmacevtski sestavek, ki vsebuje olmesartan medoksomil

Also Published As

Publication number Publication date
JPWO2008001734A1 (ja) 2009-11-26
TWI492747B (zh) 2015-07-21
CA2656181C (en) 2011-09-06
JP5769362B2 (ja) 2015-08-26
US20100237530A1 (en) 2010-09-23
WO2008001734A1 (en) 2008-01-03
TW200815000A (en) 2008-04-01
EP2033643A1 (en) 2009-03-11
KR101628028B1 (ko) 2016-06-08
CN101478966A (zh) 2009-07-08
JP2014024874A (ja) 2014-02-06
CA2656181A1 (en) 2008-01-03
EP2033643A4 (en) 2013-01-02
CN101478966B (zh) 2013-08-21
KR20090021184A (ko) 2009-02-27

Similar Documents

Publication Publication Date Title
BRPI0713371A2 (pt) método para a produção de um produto medicamentoso contendo olmesartan medoxomil, e, produto medicamentoso contendo olmesartan medoxomil
CL2008002394A1 (es) Depsipeptido ciclico, o derivados, inhibidores de calicreína 7, obtenidos desde chondromyces crocatus, metodo de obtencion y usos terapeuticos.
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
EA201171481A1 (ru) Способ получения высококонцентрированного препарата иммуноглобулина для подкожного применения
UY30711A1 (es) Nuevos derivados de 1,4-benzotiepina-1, 1-cioxido, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.-
TW200732447A (en) Adhesive formulation, method for the production thereof, and use thereof
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
BRPI0711889B8 (pt) método para produção de sinvastatina, composição de matéria, método para fabricação de huvastatina, método para fabricação de sinvastatina, e método para fabricação de uma composição de matéria de sinvastatina ou huvastatina
BR112014018378A8 (pt) Processo contínuo para a preparação de um comprimido compreendendo ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico
BRPI0905733A2 (pt) "composição, formulação farmacêutica, método para tratamento de câncer positivo para her2 e método pára a produção de uma composição farmacêutica"
BRPI0519496A2 (pt) processo para preparar um composto ou uma composiÇço, e, composiÇço
MX2009001983A (es) Compuesto que contiene dioxido de titanio.
UY30712A1 (es) Nuevos derivados de 1, 4-benzotiepina-1, 1-dioxido sustituidos con fluor, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
BRPI0924136B8 (pt) composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma
WO2009034559A3 (en) Cosmetic process for aesthetic and/or repairing treatment of the skin
UA103500C2 (uk) Сульфоксимінзаміщені анілінопіримідинові похідні як cdk-інгібітори, їх одержання й застосування як лікарських засобів
ECSP056156A (es) Procedimiento y composiciones farmacéuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
CL2012000024A1 (es) Composicion farmaceutica que comprende 100 a 2000 mg de metformina y 10 a 300 mg de un compuesto inhibidor de sglt-2 derivado de glucopiranosil fenil sustituidos, celulosa microcristalina, un aglutinante y croscaramelosa.
BRPI0508557A (pt) composição farmacêutica que compreende pimobendan
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
EA201070918A1 (ru) Применение ранолазина для лечения сердечно-сосудистых заболеваний
BRPI0416188A (pt) formulações de medicamentos que contêm aromatizante, com propriedades farmacêuticas aperfeiçoadas
PL1845957T3 (pl) Sposób uzyskiwania ekstraktu leku zawierającego hydroksystylben

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal: appeal against refusal